Vigonvita Life Sciences (HKG:2630) said the stabilization period for its global offering ended on Dec. 3, with no stabilizing actions taken, according to a Wednesday Hong Kong bourse filing.
The company said there was no over-allocation of H shares in the international offering, and the overallotment option granted to the international underwriters lapsed unexercised on Dec. 3.
No additional H shares were or will be issued.
Vigonvita added that it continues to meet the public float requirement under listing rules.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments